Cargando…

Cabozantinib exposure–response analysis for the phase 3 CheckMate 9ER trial of nivolumab plus cabozantinib versus sunitinib in first-line advanced renal cell carcinoma

PURPOSE: In the phase 3 CheckMate 9ER trial, intravenous nivolumab (240 mg every 2 weeks) plus oral cabozantinib (40 mg/day) improved progression-free survival (PFS) versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC). To support cabozantinib dosing with the combination, t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tran, Benjamin Duy, Li, Jing, Ly, Neang, Faggioni, Raffaella, Roskos, Lorin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9905187/ https://www.ncbi.nlm.nih.gov/pubmed/36625894 http://dx.doi.org/10.1007/s00280-022-04500-9

Ejemplares similares

Population Pharmacokinetics and Exposure–Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer
por: Ly, Neang S., et al.
Publicado: (2023)

Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial
por: Yau, Thomas, et al.
Publicado: (2023)

Erweiterung der Kombinationsmöglichkeiten in der Erstlinientherapie des metastasierten klarzelligen Nierenzellkarzinoms mit Nivolumab plus Cabozantinib: Ergebnisse der CheckMate-9ER-Studie
por: Oing, Christoph, et al.
Publicado: (2021)

Long-term follow-up results of nivolumab plus cabozantinib versus sunitinib for advanced renal cell cancer: Checkmate 9ER trial
por: Tarigopula, Vivek
Publicado: (2022)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
por: Motzer, Robert J, et al.
Publicado: (2022)

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
por: Ready, Neal, et al.
Publicado: (2018)

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
por: Janjigian, Yelena Y., et al.
Publicado: (2018)

CheckMATE tutorial
por: Kim, Jong Soo, et al.
Publicado: (2021)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2018)

Cost-Effectiveness of Nivolumab Plus Cabozantinib Versus Sunitinib as a First-Line Treatment for Advanced Renal Cell Carcinoma in the United States
por: Li, SiNi, et al.
Publicado: (2021)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
por: Amin, Asim, et al.
Publicado: (2019)

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up
por: Tomita, Yoshihiko, et al.
Publicado: (2019)

Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
por: Wang, Hao, et al.
Publicado: (2022)

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
por: Albiges, Laurence, et al.
Publicado: (2020)

Implementation of ML searches in CheckMATE
por: Rolbiecki, Krzysztof
Publicado: (2022)

Recent developments in CheckMATE 2
por: Wang, Zeren Simon
Publicado: (2021)

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
por: Tawbi, Hussein A, et al.
Publicado: (2021)

Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920
por: Emamekhoo, Hamid, et al.
Publicado: (2021)

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)
por: Sangro, Bruno, et al.
Publicado: (2023)

First-line nivolumab + ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
por: O’Byrne, K.J., et al.
Publicado: (2022)

Cabozantinib/ipilimumab/nivolumab interaction: Haemophagocytic lymphohistiocytosis: case report
Publicado: (2021)

CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
por: Lee, Alexandria T M, et al.
Publicado: (2023)

Implementation of multi-bin searches in CheckMATE
por: Lara Perez, Iñaki
Publicado: (2022)

Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
por: Geynisman, Daniel M., et al.
Publicado: (2022)

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study
por: Vano, Yann‐Alexandre, et al.
Publicado: (2022)

Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143
por: Omuro, Antonio, et al.
Publicado: (2022)

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
por: Fizazi, Karim, et al.
Publicado: (2022)

Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451
por: Owonikoko, Taofeek K., et al.
Publicado: (2021)

From CheckMate 227 to CheckMate 9LA: rethinking the status of chemotherapy in the immunotherapy era—chemo-free or chemo-reform?
por: Deng, Haiyi, et al.
Publicado: (2021)

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial
por: Yau, Thomas, et al.
Publicado: (2020)

Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma
por: Wiecek, Witold, et al.
Publicado: (2016)

Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial
por: Lin, Yan, et al.
Publicado: (2023)

First‐line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis
por: Liu, Tianshu, et al.
Publicado: (2022)

Case Report: Exceptional response to nivolumab plus cabozantinib in a patient with extrarenal clear cell renal cell carcinoma
por: Jansen, Caroline S., et al.
Publicado: (2023)

Complete response of metastatic papillary renal cell carcinoma with inferior vena cava tumor thrombus to nivolumab plus cabozantinib
por: Hayashida, Michikata, et al.
Publicado: (2023)

EWino searches in CheckMate and $(g-2)_\mu$ in the MSSM
por: Chakraborti, Manimala
Publicado: (2021)

Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227
por: Brahmer, Julie R., et al.
Publicado: (2023)

Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
por: Haddad, Robert I., et al.
Publicado: (2023)

Nivolumab versus everolimus in advanced renal cell carcinoma: Japanese subgroup analysis from the CheckMate 025 study
por: Tomita, Yoshihiko, et al.
Publicado: (2017)

Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial
por: Reardon, David A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4bu0qha5kgl60jm5nnmalimngq